- Hemophilia A
- Hemophilia B
- Hemophilia C
- Others
Hemophilia Treatment Market was valued at USD 9,834.7 million in 2022 and is projected to reach USD 15,387.3 Million by 2029, growing at a 5.2% CAGR from 2023 to 2029. Hemophilia is an inherited bleeding disorder that is caused by the lack of clotting proteins, a patient suffering from hemophilia bleeds longer than usual or even bleeds internally. The primary treatment for is to replace the missing clotting factor through intravenous infusion. The rising prevalence of hemophilia across the world and technological advancement in medications drive market growth. According to the Centres for disease control and Prevention, Hemophilia A affects 1 in 5,000 male births. About 400 babies are born with hemophilia, each year, as many as 33,000 males in the United States are living with the disorder. The growing adoption of prophylaxis treatment and the upsurge of hemophilia prevalence in newborns enhance the market growth. The government initiatives for the promotion of hemophilia treatment and increase in research and development on identifying therapeutic agent consequences lucrative opportunities in the market. The increased cost of medications and rising adverse reactions of plasma treatment products are the major factors limiting market growth.
Study Period
Base Year
CAGR
Largest Market
Fastest Growing Market
The increasing prevalence of hemophilia patients across the world is the major market driver in the hemophilia treatment market during the forecast period. Hemophilia is caused when blood is unable to clot properly, excessive bleeding occurs after an injury. The rising prevalence of hemophilia observed in the past years, the continuous research and development activities enhance the market growth, in recent studies the current population of males with hemophilia in the United States is estimated to be between 30,000 to 33,000 consequences of high demand for therapeutic agents to prevent from hemophilia. Technological advancement in healthcare for diagnosis drives market growth at a significant rate.
The haemophilia treatment market size is expected to be valued at USD 1,636.5 million in 2022.
The haemophilia treatment market is poised to grow at a significant CAGR of 9.8% from 2023 to 2029.
The leading players in the haemophilia treatment market are Baxter, Grifols S.A., CSL Limited, Octapharma, Novo Nordisk A/S, Kedrion S.p.A, Pfizer Inc., Bayer AG, Biogen, Shire, F. Hoffmann-La Roche Ltd, Ferring B.V., Sanofi, Swedish Orphan Biovitrum AB (publ), BioMarin, and Sangamo Therapeutics,
Historic years considered for the market study are 2018 through 2022, 2022 is considered as the base year for market estimation and Seven years forecast presented from 2023 – 2029.
1.Executive Summary |
2.Global Haemophilia Treatment Market Introduction |
2.1.Global Haemophilia Treatment Market - Taxonomy |
2.2.Global Haemophilia Treatment Market - Definitions |
2.2.1.Type |
2.2.2.Product Type |
2.2.3.Distribution Channel |
2.2.4.Region |
3.Global Haemophilia Treatment Market Dynamics |
3.1. Drivers |
3.2. Restraints |
3.3. Opportunities/Unmet Needs of the Market |
3.4. Trends |
3.5. Product Landscape |
3.6. New Product Launches |
3.7. Impact of COVID 19 on Market |
4.Global Haemophilia Treatment Market Analysis, 2018 - 2022 and Forecast 2023 - 2029 |
4.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) |
4.3. Market Opportunity Analysis |
5.Global Haemophilia Treatment Market By Type, 2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
5.1. Hemophilia A |
5.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
5.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.1.3. Market Opportunity Analysis |
5.2. Hemophilia B |
5.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
5.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.2.3. Market Opportunity Analysis |
5.3. Hemophilia C |
5.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
5.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.3.3. Market Opportunity Analysis |
5.4. Others |
5.4.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
5.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.4.3. Market Opportunity Analysis |
6.Global Haemophilia Treatment Market By Product Type, 2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
6.1. Plasma-Derived Coagulation Factor Concentrates |
6.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
6.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.1.3. Market Opportunity Analysis |
6.2. Recombinant Coagulation Factor Concentrates |
6.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
6.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.2.3. Market Opportunity Analysis |
6.3. Desmopressin |
6.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
6.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.3.3. Market Opportunity Analysis |
6.4. Antifibrinolytic Agents |
6.4.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
6.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.4.3. Market Opportunity Analysis |
7.Global Haemophilia Treatment Market By Distribution Channel, 2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
7.1. Hospital Pharmacy |
7.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
7.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.1.3. Market Opportunity Analysis |
7.2. Retail Pharmacy |
7.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
7.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.2.3. Market Opportunity Analysis |
7.3. Online Pharmacy |
7.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
7.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.3.3. Market Opportunity Analysis |
8.Global Haemophilia Treatment Market By Region, 2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
8.1. North America |
8.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
8.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.1.3. Market Opportunity Analysis |
8.2. Europe |
8.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
8.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.2.3. Market Opportunity Analysis |
8.3. Asia Pacific (APAC) |
8.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
8.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.3.3. Market Opportunity Analysis |
8.4. Middle East and Africa (MEA) |
8.4.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
8.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.4.3. Market Opportunity Analysis |
8.5. Latin America |
8.5.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million) |
8.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.5.3. Market Opportunity Analysis |
9.North America Haemophilia Treatment Market ,2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
9.1. Type Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
9.1.1.Hemophilia A |
9.1.2.Hemophilia B |
9.1.3.Hemophilia C |
9.1.4.Others |
9.2. Product Type Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
9.2.1.Plasma-Derived Coagulation Factor Concentrates |
9.2.2.Recombinant Coagulation Factor Concentrates |
9.2.3.Desmopressin |
9.2.4.Antifibrinolytic Agents |
9.3. Distribution Channel Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
9.3.1.Hospital Pharmacy |
9.3.2.Retail Pharmacy |
9.3.3.Online Pharmacy |
9.4. Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
9.4.1.United States of America (USA) |
9.4.2.Canada |
10.Europe Haemophilia Treatment Market ,2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
10.1. Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
10.1.1.Hemophilia A |
10.1.2.Hemophilia B |
10.1.3.Hemophilia C |
10.1.4.Others |
10.2. Product Type Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
10.2.1.Plasma-Derived Coagulation Factor Concentrates |
10.2.2.Recombinant Coagulation Factor Concentrates |
10.2.3.Desmopressin |
10.2.4.Antifibrinolytic Agents |
10.3. Distribution Channel Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
10.3.1.Hospital Pharmacy |
10.3.2.Retail Pharmacy |
10.3.3.Online Pharmacy |
10.4. Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
10.4.1.Germany |
10.4.2.France |
10.4.3.Italy |
10.4.4.United Kingdom (UK) |
10.4.5.Spain |
10.4.6.Rest of EU |
11.Asia Pacific (APAC) Haemophilia Treatment Market ,2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
11.1. Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
11.1.1.Hemophilia A |
11.1.2.Hemophilia B |
11.1.3.Hemophilia C |
11.1.4.Others |
11.2. Product Type Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
11.2.1.Plasma-Derived Coagulation Factor Concentrates |
11.2.2.Recombinant Coagulation Factor Concentrates |
11.2.3.Desmopressin |
11.2.4.Antifibrinolytic Agents |
11.3. Distribution Channel Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
11.3.1.Hospital Pharmacy |
11.3.2.Retail Pharmacy |
11.3.3.Online Pharmacy |
11.4. Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
11.4.1.China |
11.4.2.India |
11.4.3.Australia and New Zealand (ANZ) |
11.4.4.Japan |
11.4.5.Rest of APAC |
12.Middle East and Africa (MEA) Haemophilia Treatment Market ,2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
12.1. Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
12.1.1.Hemophilia A |
12.1.2.Hemophilia B |
12.1.3.Hemophilia C |
12.1.4.Others |
12.2. Product Type Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
12.2.1.Plasma-Derived Coagulation Factor Concentrates |
12.2.2.Recombinant Coagulation Factor Concentrates |
12.2.3.Desmopressin |
12.2.4.Antifibrinolytic Agents |
12.3. Distribution Channel Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
12.3.1.Hospital Pharmacy |
12.3.2.Retail Pharmacy |
12.3.3.Online Pharmacy |
12.4. Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
12.4.1.GCC Countries |
12.4.2.South Africa |
12.4.3.Rest of MEA |
13.Latin America Haemophilia Treatment Market ,2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million) |
13.1. Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
13.1.1.Hemophilia A |
13.1.2.Hemophilia B |
13.1.3.Hemophilia C |
13.1.4.Others |
13.2. Product Type Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
13.2.1.Plasma-Derived Coagulation Factor Concentrates |
13.2.2.Recombinant Coagulation Factor Concentrates |
13.2.3.Desmopressin |
13.2.4.Antifibrinolytic Agents |
13.3. Distribution Channel Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
13.3.1.Hospital Pharmacy |
13.3.2.Retail Pharmacy |
13.3.3.Online Pharmacy |
13.4. Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
13.4.1.Brazil |
13.4.2.Mexico |
13.4.3.Rest of LA |
14. Competition Landscape |
14.1. Market Player Profiles (Introduction, Brand/Product Sales, Financial Analysis, Product Offerings, Key Developments, Collaborations, M & A, Strategies, and SWOT Analysis) |
14.2.1.Baxter |
14.2.2.Grifols S.A. |
14.2.3.CSL Limited |
14.2.4.Octapharma |
14.2.5.Novo Nordisk A/S |
14.2.6.Kedrion S.p.A |
14.2.7.Pfizer Inc. |
14.2.8.Bayer AG |
14.2.9.Biogen |
14.2.10.Shire |
14.2.11.F. Hoffmann-La Roche Ltd |
14.2.12.Ferring B.V. |
15. Research Methodology |
16. Appendix and Abbreviations |